Page 1,633«..1020..1,6321,6331,6341,635..1,6401,650..»

Department of Cell Biology and Physiology, School of …

Posted: March 5, 2017 at 9:41 am

Message From Our Chair

Welcome to the Department of Cell Biology and Physiology in the School of Medicine at the University of North Carolina at Chapel Hill where our mission is to be nationally recognized for excellence in our discipline by Leading, Teaching and Caring.

LeadingWe conduct cutting-edge, innovative research that advances the discipline of cell biology and physiology, with an emphasis on topics that contribute to the improvement of human health. The UNC-CH Department of Cell Biology and Physiology is nationally-recognized and ranked #2 in the country for our level of NIH funding in 2016! The Department comprises over 35 basic science laboratories dedicated to integrative research in areas related to neuroscience, cardiovascular development and disease, cell motility, cellular cytoskeleton and intracellular trafficking, gastrointestinal biology, cellular mechanisms of aging and cancer biology. I encourage you to browse our website, which highlights each individual faculty research program. Our faculty, trainees and staff benefit from robust partnerships with numerous Centers across campus including the Lineberger Comprehensive Cancer Center, McAllister Heart Institute, Marsico Lung Institute and Thurston Arthritis Research Center, to name a few.

TeachingWe provide a rigorous and competitive educational experience for a diverse population of graduate and professional trainees which enables them to succeed in their future careers. The Department has a long tradition of successfully training the next generation of scientists. Our newly-launched Curriculum in Cell Biology and Physiology offers an integrated training program for PhD students. In addition, the Department is home to a multitude of undergraduate, medical and clinical fellow trainees who are seeking avenues for intellectually-engaging and creative research experiences. Research scientists who train in the discipline of cell biology and physiology will benefit from being able to synergize their training from several vantage points. For example, the development of sophisticated genetic engineering tools enables us to test focused hypotheses on the multi-cellular diversity of organs and their cellular compositions. Likewise, these same genetic techniques, coupled with the ability to image cell behavior at unprecedented resolution and the application of -omics approaches, permits a broader exploration into how cells sense and respond to their environments, either within an organ or in response to different pathophysiological conditions. In these ways, research trainees in our Department can capitalize on rapid technological advances and successfully apply their findings to inform the fundamental processes of normal and pathological physiology and cell biological behaviors.

CaringWe serve the people of North Carolina, the United States and the international community, by excelling in our research and educational missions thereby promoting the health and well-being of individuals and communities locally, nationally and internationally. The Department of Cell Biology and Physiology has a strong commitment to fostering an environment of inclusion, diversity and wellness within the workplace, which lays the foundation for collaborative partnerships and creative exploration. We provide award-wining mentoring and professional development activities for individuals at all career stages. Our faculty and trainees actively participate in local and national service, giving back to our communities.

It is an exciting time for the Department, with six new faculty hires, the launch of our state-of-the-art Hooker Imaging Core Facility and remarkable accolades and recognition of our distinguished faculty and trainees. I hope that you will enjoy exploring our research and educational programs, and encourage you to contact us if you would like to join and support our missions.

Read more:
Department of Cell Biology and Physiology, School of ...

Posted in Cell Medicine | Comments Off on Department of Cell Biology and Physiology, School of …

Opinion/Commentary: Global stem cell therapy market to showcase growth – The Daily Progress

Posted: March 5, 2017 at 9:41 am

LONDON Technavio analysts forecast the global stem cell therapy market to grow at a compound annual growth rate of close to 37 percent during the forecast period, according to their latest report.

The research study covers the present scenario and growth prospects of the global stem cell therapy market for 2017-2021. To determine the market size, the study considers revenue generated from allogenic and autogenic stem cell therapies.

The Americas are the largest regional segment of the global stem cell therapy market, responsible for generating over 56 percent of the total revenue (2016 figures). The region is expected to continue market dominance through the forecast period, driven by increasing demand for stem cell therapy products and investments into R&D.

Technavio analysts highlight the following factors as contributing to the growth of the global stem cell therapy market:

Increase in federal funding in stem cell therapy.

Sapna Jha, one of the lead research analysts at Technavio for medical imaging research, says, Many stem cell research institutes and small companies are involved in cutting-edge R&D and are yielding encouraging results. These institutions are witnessing an increased flow of investments from federal organizations, due to the realization of the importance of regenerative medicine.

The U.S. National Institutes of Health, a major funding government organization invested approximately USD 1.5 billion in stem cell research projects in 2016. Similarly, several state-level organizations such as California Institute for Regenerative Medicine has contributed USD 3 billion to stem cell research in 2014. Such funding will help various research institutes to discover and develop regenerative medicines, which will boost the global regenerative medicine market enormously.

Growing demand for personalized medicine.

The health care sector is creating a high demand for personalized medicine, which could offer game-changing opportunities for the vendors. These medicines offer treatments based on the individual characteristics, needs, and preferences, which will vastly improve the quality of health care. Individuals are increasingly banking their stem cells for future treatments. Research organizations are also extensively exploring ways to develop personalized treatments with stem cells, which could eventually erase the conventional medicine system and help in the effective treatment of various diseases such as diabetes and cancer.

Demand for development of effective drugs for cardiology and degenerative disorders.

There has been an increased demand to develop effective drugs for cardiology and degenerative disorders, for which there were no effective treatment plans before the advent of stem therapies. The discovery of possible cardiac stem cells uncovered new arenas to repair hearts injured due to acute myocardial infarction or coronary artery disease, says Sapna.

Researchers are studying and developing approximately 19 product candidates for the treatment of cardiac disorders, with eight of them in Phase III, and six in Phase II.

Technavio is a global technology research and advisory company. This report was made available through The Associated Press.

Visit link:
Opinion/Commentary: Global stem cell therapy market to showcase growth - The Daily Progress

Posted in Cell Therapy | Comments Off on Opinion/Commentary: Global stem cell therapy market to showcase growth – The Daily Progress

Diabetes prevention help offered – Burlington Times News

Posted: March 5, 2017 at 9:40 am

Kyle Lubinsky / Times-News

Alamance Regional Medical Center has partnered with the county health department to teach a class directed toward diabetes prevention in nine area counties.

Diabetes affects a startling number of people in the United States: Nearly 30 million Americans have it.

In North Carolina, its about 1,075,855, roughly 13.1 percent of the adult population. An additional 2.6 million, or 36.1 percent of adults, have pre-diabetes, which means they have high blood glucose levels that arent quite high enough to be diagnosed as diabetes.

We hear it all the time, that we have to eat right and exercise, said Rachel Marquez, master trainer for the diabetes program. However, its about small, sustainable life changes.

The class started in 2015, and so far has seen six groups complete the year-long program. Each program is open to people who are pre-diabetic, and each section is limited to 15 people, although Marquez says she usually averages seven to eight at any given time.

Initially, the program was held at Blessed Sacrament Church. After seeing positive results, the hospital decided to open a class to employees at ARMC. The current class, which graduated Feb. 16, consisted of 14 participants who lost an average of 5.5 percent of their body weight. That reduces individual chances of developing diabetes by 50 to 70 percent.

Marquez has seen a wide variety of participants with a wide variety of motives for taking the class everything from wanting to play with their grandchildren to wanting to get off of their medication. The class has given many of those involved results: Marquez has noticed weight loss and a general decrease in pain in participants at the end of the year.

Rick Settle is one such participant. The registered phlebotomist goes out into the local community around the hospital and tests blood for syphilis and hepatitis C. Over the past few years, his hemoglobin A1C test, which is used to determine whether an adult is diabetic, revealed that he was pre-diabetic. When the program was opened to employees, he ran into Marquez, who encouraged him to join.

Over the next year, Settle lost 43 pounds, and his A1C levels when back down to a healthy number. The positive atmosphere in the class helped him to push through tough times it felt as if everyone was working toward a common goal.

The best part was the encouragement, Settle said. It wasnt as much a competition as it was encouragement. The pounds came off when I watched what I was eating.

The class encouraged Settle and other participants to count their fat grams as they are the most important part of losing weight and keeping it off. It also helped him to form good habits, and the knee problems he had when starting the program have lessened as well.

The main benefit that I saw was a result of the weight loss, he said. As long as I can keep this going, I wont have to take any medication.

Excerpt from:
Diabetes prevention help offered - Burlington Times News

Posted in Diabetes | Comments Off on Diabetes prevention help offered – Burlington Times News

Lilly Diabetes expands role with NASCAR as ‘Official Health Partner … – FOXSports.com

Posted: March 5, 2017 at 9:40 am

One week after winning the XFINITY race at Daytona as the primary sponsor on Ryan Reeds No. 16 Roush Fenway Racing Ford, Lilly Diabetes is expanding its role with NASCAR.

NASCAR and Lilly Diabetes announced Friday that Lilly has signed a multi-year partnership with the sport to serve as the Official Diabetes Health Partner of NASCAR.

The new partnership will feature multiple health and wellness initiatives along with an editorial series on NASCAR.com

As a leader in diabetes care for more than 90 years, we understand the daily challenges that millions of Americans face managing this disease, said Mike Mason, vice president, U.S., Lilly Diabetes. Our partnership with NASCAR, along with our continued relationship with Ryan, emphasizes the critical role of ongoing discussions with your doctor about how to best manage the disease.

Lilly Diabetes joined the NASCAR community in 2013 with its first sponsorship of Ryan Reed in the XFINITY Series. Reed has Type 1 Diabetes and has used the sponsorship to raise awareness about the disease and to help fans take action to better manage their diabetes.

Our program with Lilly Diabetes is one that touches my life in a significant way, being diagnosed with type 1 diabetes at the age of 17, said Reed. I have seen the positive effect our partnership with Lilly Diabetes has had on those impacted by this disease, and I cant wait to see what NASCAR and Lilly can accomplish together.

FOX Fantasy Auto Form a Racing Team, Compete for Prizes

Original post:
Lilly Diabetes expands role with NASCAR as 'Official Health Partner ... - FOXSports.com

Posted in Diabetes | Comments Off on Lilly Diabetes expands role with NASCAR as ‘Official Health Partner … – FOXSports.com

Star Wars Characters attend Diabetes Screening Event – WTXL ABC 27

Posted: March 5, 2017 at 9:40 am

TALLAHASSEE, Fla. (WTXL) - According to the American Diabetes Association, more than 29 million Americans have diabetes.

The association also estimates that more than 8 million are living with the condition and remain undiagnosed.

That's why Saturday, Bond Community Health Center and the Rotary Club of Tallahassee, teamed up to help locals with concerns about diabetes.

The people who came out found some familiar faces as members of the Star Wars family came to the event to help out, interacting with patients.

The event allowed those who are at risk to ask questions of medical professionals and receive expert advice.

Iris Hannah, who has recently been diagnosed with diabetes, says the event was 'life changing' and allowed her to finally receive the medical help she had been seeking for months.

"I found out today through this that my numbers for diabetes was in the hundreds. I'm at a place were I was almost a walking dead woman and I didn't even know that my numbers were that high," said Hannah. "It has been a great experience. I mean everyone here who has volunteered has given me the best assistance and information that I need to get my numbers down."

30 people were screened during this event. It was the inaugural event for the organization and they expect to serve more residents next year.

Read this article:
Star Wars Characters attend Diabetes Screening Event - WTXL ABC 27

Posted in Diabetes | Comments Off on Star Wars Characters attend Diabetes Screening Event – WTXL ABC 27

Increased rates of diabetes and obesity are a reality in Oregon | News – NRToday.com

Posted: March 5, 2017 at 9:40 am

William Howell has seen first-hand the dangers of a disease that almost took his life. It is one that strikes slowly but is deadly, often leaving its victims permanently disabled if not treated. The disease causes high blood glucose levels due to a lack of insulin production.

Howell of Roseburg has struggled with Type 2 diabetes since the age of 26. He has been able to manage it through daily insulin shots.

But four years ago, Howell, then 51, fell into a severe coma. This was shortly after eating a dinner full of mashed potatoes, corn, steak and a glass of chocolate milk. Doctors wondered if he would recover.

I had too high of blood sugar, Howell said. I didnt even realize it. I was eating and drinking what I wanted and all of that contributed to it.

Howell, a 228-pound, 56-year-old man, lived a life full of drinking 2-liter bottles of soda daily and constantly eating sweets. Obesity and permanent blindness left him unable to do the activities he once enjoyed. In addition to insulin shots, he undergoes dialysis three days a week, exercises regularly and has a healthier diet.

He said an unhealthy diet, lack of exercise and obesity played an important role in the onset of the disease.

If you dont want kidney dialysis and if you dont want to go blind, dont do the stuff thats not good for you and try living a healthier lifestyle, he said.

Increased rates of obesity and diabetes are ongoing problems in Douglas County, according to reports from the Oregon Health Authority. Diagnosed cases of diabetes increased by nearly 9 percentage points to 14.6 percent in 2015, while obesity increased by about 3 percentage points to 35.4 percent during the same time period, according to unadjusted data collected by OHA.

Unadjusted rates indicate the burden of a disease over a concentrated population in a single geographical area while age-adjusted rates are used among multiple populations that vary by age.

In response to these ongoing issues, the OHA awarded Douglas County a Healthy Communities grant of $64,695 to promote healthy living options for the community. This grant provides healthy nutritional food and physical activities at schools as well as Wellness at Work programs which include healthy food, exercise breaks and tobacco-free work sites, said Jonathan Modie, an OHA spokesman. It also provides healthy choices to churches and community centers with partners including Oregon Walks, AARP, YMCA and Mercy Medical Center.

Douglas Countys obesity and diabetes rates are higher than statewide data, suggest reports from OHA.

Oregons obesity rate increased by nearly 5 percentage points to 27.1 percent in 2015, according to age-adjusted data. During the same time period, the number of diagnosed cases of diabetes increased by about 5 percentage points to 8.6 percent. Out of the 50 states and Washington D.C., Oregon ranks in the bottom half in both categories 28th for obesity and 31st for diabetes.

These unsettling statistics not only indicate a rise in both diseases, but also how one may be a primary indicator of the other. The single best predictor of Type 2 diabetes is obesity, Modie said.

Health professionals have concerns about how these issues impact a patients overall long-term health.

Jill Boyce, a registered dietitian and the diabetes program coordinator at Cow Creek Health & Wellness Center, said diabetes can affect a persons mental, emotional and physical well-being.

As a dietitian, it is concerning to see this epidemic since obesity and diabetes are preventable, she said. It can impact not only themselves but also the people around them and increase their risk factors for other chronic diseases.

Boyce said the most prominent prevention of diabetes-related illness is education and awareness on making healthy food choices and learning the benefits of increased physical activity.

The Cow Creek Health and Wellness Centers Special Diabetes Program is a six to 12-month program aiding in the prevention of diabetes. It addresses statistics indicating that diabetes is more prevalent among Native Americans than many other racial and ethnic groups in America. So far its been discovered that the most prevalent type of diabetes among Native Americans, Type 2, can be kept at bay through exercise and healthy nutrition. This is also true among all populations.

To address statewide health issues, the OHAs Public Health Division currently funds Benton, Douglas, Lane, and Multnomah counties. In addition, it funds the Coquille Indian Tribe.

Its primary focus is toward eliminating physical inactivity and poor nutrition by addressing community-based activities such as increasing access to nutritious food, encouraging people to be more physically active and increasing access to self-sustainability programs. Additionally, OHA is partnering with healthcare payers to increase the availability of programs such as the National Diabetes Prevention Program and Chronic Disease Self-Management programs, said Modie.

Without making meaningful changes to make it easier for people to eat nutritious food, avoid unhealthy foods and move more, Oregon will not be able to decrease adult or youth obesity, he said. Addressing the pervasive marketing and promotion of unhealthy food and supporting communities to make long term changes to build environments where physical activity is an essential part of everyones life.

View original post here:
Increased rates of diabetes and obesity are a reality in Oregon | News - NRToday.com

Posted in Diabetes | Comments Off on Increased rates of diabetes and obesity are a reality in Oregon | News – NRToday.com

Human cloning – Wikipedia

Posted: March 4, 2017 at 10:46 am

Human cloning is the creation of a genetically identical copy of a human. The term is generally used to refer to artificial human cloning, which is the reproduction of human cells and tissue. It does not refer to the natural conception and delivery of identical twins. The possibility of human cloning has raised controversies. These ethical concerns have prompted several nations to pass laws regarding human cloning and its legality.

Two commonly discussed types of theoretical human cloning are: therapeutic cloning and reproductive cloning. Therapeutic cloning would involve cloning cells from a human for use in medicine and transplants, and is an active area of research, but is not in medical practice anywhere in the world, as of January 2017[update]. Two common methods of therapeutic cloning that are being researched are somatic-cell nuclear transfer and, more recently, pluripotent stem cell induction. Reproductive cloning would involve making an entire cloned human, instead of just specific cells or tissues.

Although the possibility of cloning humans had been the subject of speculation for much of the 20th century, scientists and policy makers began to take the prospect seriously in the mid-1960s.

Nobel Prize-winning geneticist Joshua Lederberg advocated cloning and genetic engineering in an article in The American Naturalist in 1966 and again, the following year, in The Washington Post.[1] He sparked a debate with conservative bioethicist Leon Kass, who wrote at the time that "the programmed reproduction of man will, in fact, dehumanize him." Another Nobel Laureate, James D. Watson, publicized the potential and the perils of cloning in his Atlantic Monthly essay, "Moving Toward the Clonal Man", in 1971.[2]

With the cloning of a sheep known as Dolly in 1996 by somatic cell nuclear transfer (SCNT), the idea of human cloning became a hot debate topic.[3] Many nations outlawed it, while a few scientists promised to make a clone within the next few years. The first hybrid human clone was created in November 1998, by Advanced Cell Technology. It was created using SCNT - a nucleus was taken from a man's leg cell and inserted into a cow's egg from which the nucleus had been removed, and the hybrid cell was cultured, and developed into an embryo. The embryo was destroyed after 12 days.[4]

In 2004 and 2005, Hwang Woo-suk, a professor at Seoul National University, published two separate articles in the journal Science claiming to have successfully harvested pluripotent, embryonic stem cells from a cloned human blastocyst using somatic-cell nuclear transfer techniques. Hwang claimed to have created eleven different patent-specific stem cell lines. This would have been the first major breakthrough in human cloning.[5] However, in 2006 Science retracted both of his articles on clear evidence that much of his data from the experiments was fabricated.[6]

In January 2008, Dr. Andrew French and Samuel Wood of the biotechnology company Stemagen announced that they successfully created the first five mature human embryos using SCNT. In this case, each embryo was created by taking a nucleus from a skin cell (donated by Wood and a colleague) and inserting it into a human egg from which the nucleus had been removed. The embryos were developed only to the blastocyst stage, at which point they were studied in processes that destroyed them. Members of the lab said that their next set of experiments would aim to generate embryonic stem cell lines; these are the "holy grail" that would be useful for therapeutic or reproductive cloning.[7][8]

In 2011, scientists at the New York Stem Cell Foundation announced that they had succeeded in generating embryonic stem cell lines, but their process involved leaving the oocyte's nucleus in place, resulting in triploid cells, which would not be useful for cloning.[10][11]

In 2013, a group of scientists led by Shoukhrat Mitalipov published the first report of embryonic stem cells created using SCNT. In this experiment, the researchers developed a protocol for using SCNT in human cells, which differs slightly from the one used in other organisms. Four embryonic stem cell lines from human fetal somatic cells were derived from those blastocysts. All four lines were derived using oocytes from the same donor, ensuring that all mitochondrial DNA inherited was identical. A year later, a team led by Robert Lanza at Advanced Cell Technology reported that they had replicated Mitalipov's results and further demonstrated the effectiveness by cloning adult cells using SCNT.[3][12]

In somatic cell nuclear transfer ("SCNT"), the nucleus of a somatic cell is taken from a donor and transplanted into a host egg cell, which had its own genetic material removed previously, making it an enucleated egg. After the donor somatic cell genetic material is transferred into the host oocyte with a micropipette, the somatic cell genetic material is fused with the egg using an electric current. Once the two cells have fused, the new cell can be permitted to grow in a surrogate or artificially.[13] This is the process that was used to successfully clone Dolly the sheep (see section on History in this article).[3]

Creating induced pluripotent stem cells ("iPSCs") is a long and inefficient process. Pluripotency refers to a stem cell that has the potential to differentiate into any of the three germ layers: endoderm (interior stomach lining, gastrointestinal tract, the lungs), mesoderm (muscle, bone, blood, urogenital), or ectoderm (epidermal tissues and nervous system).[14] A specific set of genes, often called "reprogramming factors", are introduced into a specific adult cell type. These factors send signals in the mature cell that cause the cell to become a pluripotent stem cell. This process is highly studied and new techniques are being discovered frequently on how to better this induction process.

Depending on the method used, reprogramming of adult cells into iPSCs for implantation could have severe limitations in humans. If a virus is used as a reprogramming factor for the cell, cancer-causing genes called oncogenes may be activated. These cells would appear as rapidly dividing cancer cells that do not respond to the body's natural cell signaling process. However, in 2008 scientists discovered a technique that could remove the presence of these oncogenes after pluripotency induction, thereby increasing the potential use of iPSC in humans.[15]

Both the processes of SCNT and iPSCs have benefits and deficiencies. Historically, reprogramming methods were better studied than SCNT derived embryonic stem cells (ESCs). However, more recent studies have put more emphasis on developing new procedures for SCNT-ESCs. The major advantage of SCNT over iPSCs at this time is the speed with which cells can be produced. iPSCs derivation takes several months while SCNT would take a much shorter time, which could be important for medical applications. New studies are working to improve the process of iPSC in terms of both speed and efficiency with the discovery of new reprogramming factors in oocytes.[citation needed] Another advantage SCNT could have over iPSCs is its potential to treat mitochondrial disease, as it utilizes a donor oocyte. No other advantages are known at this time in using stem cells derived from one method over stem cells derived from the other.[16]

Work on cloning techniques has advanced our basic understanding of developmental biology in humans. Observing human pluripotent stem cells grown in culture provides great insight into human embryo development, which otherwise cannot be seen. Scientists are now able to better define steps of early human development. Studying signal transduction along with genetic manipulation within the early human embryo has the potential to provide answers to many developmental diseases and defects. Many human-specific signaling pathways have been discovered by studying human embryonic stem cells. Studying developmental pathways in humans has given developmental biologists more evidence toward the hypothesis that developmental pathways are conserved throughout species.[17]

iPSCs and cells created by SCNT are useful for research into the causes of disease, and as model systems used in drug discovery.[18][19]

Cells produced with SCNT, or iPSCs could eventually be used in stem cell therapy,[20] or to create organs to be used in transplantation, known as regenerative medicine. Stem cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplantation is a widely used form of stem cell therapy.[21] No other forms of stem cell therapy are in clinical use at this time. Research is underway to potentially use stem cell therapy to treat heart disease, diabetes, and spinal cord injuries.[22][23] Regenerative medicine is not in clinical practice, but is heavily researched for its potential uses. This type of medicine would allow for autologous transplantation, thus removing the risk of organ transplant rejection by the recipient.[24] For instance, a person with liver disease could potentially have a new liver grown using their same genetic material and transplanted to remove the damaged liver.[25] In current research, human pluripotent stem cells have been promised as a reliable source for generating human neurons, showing the potential for regenerative medicine in brain and neural injuries.[26]

In bioethics, the ethics of cloning refers to a variety of ethical positions regarding the practice and possibilities of cloning, especially human cloning. While many of these views are religious in origin, the questions raised by cloning are faced by secular perspectives as well. Human therapeutic and reproductive cloning are not commercially used; animals are currently cloned in laboratories and in livestock production.

Advocates support development of therapeutic cloning in order to generate tissues and whole organs to treat patients who otherwise cannot obtain transplants,[27] to avoid the need for immunosuppressive drugs,[28] and to stave off the effects of aging.[29] Advocates for reproductive cloning believe that parents who cannot otherwise procreate should have access to the technology.[30]

Opposition to therapeutic cloning mainly centers around the status of embryonic stem cells, which has connections with the abortion debate.[31]

Some opponents of reproductive cloning have concerns that technology is not yet developed enough to be safe - for example, the position of the American Association for the Advancement of Science as of 2014[update],[32] while others emphasize that reproductive cloning could be prone to abuse (leading to the generation of humans whose organs and tissues would be harvested),[33][34] and have concerns about how cloned individuals could integrate with families and with society at large.[35][36]

Religious groups are divided, with some[which?] opposing the technology as usurping God's (in monotheistic traditions) place and, to the extent embryos are used, destroying a human life; others support therapeutic cloning's potential life-saving benefits.[37][38]

In 2015 it was reported that about 70 countries had banned human cloning.[39]

Human cloning is banned by the Presidential Decree 200/97 since March 7, 1997. [40][41]

Australia has prohibited human cloning,[42] though as of December 2006[update], a bill legalizing therapeutic cloning and the creation of human embryos for stem cell research passed the House of Representatives. Within certain regulatory limits, and subject to the effect of state legislation, therapeutic cloning is now legal in some parts of Australia.[43]

Canadian law prohibits the following: cloning humans, cloning stem cells, growing human embryos for research purposes, and buying or selling of embryos, sperm, eggs or other human reproductive material.[44] It also bans making changes to human DNA that would pass from one generation to the next, including use of animal DNA in humans. Surrogate mothers are legally allowed, as is donation of sperm or eggs for reproductive purposes. Human embryos and stem cells are also permitted to be donated for research.[citation needed]

There have been consistent calls in Canada to ban human reproductive cloning since the 1993 Report of the Royal Commission on New Reproductive Technologies. Polls have indicated that an overwhelming majority of Canadians oppose human reproductive cloning, though the regulation of human cloning continues to be a significant national and international policy issue. The notion of "human dignity" is commonly used to justify cloning laws. The basis for this justification is that reproductive human cloning necessarily infringes notions of human dignity.[45][46][47][48]

Human cloning is prohibited in Article 133 of the Colombian Penal Code.[49]

The European Convention on Human Rights and Biomedicine prohibits human cloning in one of its additional protocols, but this protocol has been ratified only by Greece, Spain and Portugal. The Charter of Fundamental Rights of the European Union explicitly prohibits reproductive human cloning. The charter is legally binding for the institutions of the European Union under the Treaty of Lisbon and for member states of the Union implementing EU law.[50][51]

India does not have specific law regarding cloning but has guidelines prohibiting whole human cloning or reproductive cloning. India allows therapeutic cloning and the use of embryonic stem cells for research proposes.[52][53]

Human cloning is explicitly prohibited in Article 24, "Right to Life" of the 2006 Constitution of Serbia.[54]

In terms of section 39A of the Human Tissue Act 65 of 1983, genetic manipulation of gametes or zygotes outside the human body is absolutely prohibited. A zygote is the cell resulting from the fusion of two gametes; thus the fertilised ovum. Section 39A thus prohibits human cloning.

On January 14, 2001 the British government passed The Human Fertilisation and Embryology (Research Purposes) Regulations 2001[55] to amend the Human Fertilisation and Embryology Act 1990 by extending allowable reasons for embryo research to permit research around stem cells and cell nuclear replacement, thus allowing therapeutic cloning. However, on November 15, 2001, a pro-life group won a High Court legal challenge, which struck down the regulation and effectively left all forms of cloning unregulated in the UK. Their hope was that Parliament would fill this gap by passing prohibitive legislation.[56][57] Parliament was quick to pass the Human Reproductive Cloning Act 2001 which explicitly prohibited reproductive cloning. The remaining gap with regard to therapeutic cloning was closed when the appeals courts reversed the previous decision of the High Court.[58]

The first license was granted on August 11, 2004 to researchers at the University of Newcastle to allow them to investigate treatments for diabetes, Parkinson's disease and Alzheimer's disease.[59] The Human Fertilisation and Embryology Act 2008, a major review of fertility legislation, repealed the 2001 Cloning Act by making amendments of similar effect to the 1990 Act. The 2008 Act also allows experiments on hybrid human-animal embryos.[60]

On December 13, 2001, the United Nations General Assembly began elaborating an international convention against the reproductive cloning of humans. A broad coalition of States, including Spain, Italy, the Philippines, the United States, Costa Rica and the Holy See sought to extend the debate to ban all forms of human cloning, noting that, in their view, therapeutic human cloning violates human dignity. Costa Rica proposed the adoption of an international convention to ban all forms of human cloning. Unable to reach a consensus on a binding convention, in March 2005 a non-binding United Nations Declaration on Human Cloning, calling for the ban of all forms of human cloning contrary to human dignity, was adopted.[61][62]

In 1998, 2001, 2004, 2005, and 2007, the United States House of Representatives voted whether to ban all human cloning, both reproductive and therapeutic. Each time, divisions in the Senate over therapeutic cloning prevented either competing proposal (a ban on both forms or reproductive cloning only) from passing. On March 10, 2010 a bill (HR 4808) was introduced with a section banning federal funding for human cloning.[63] Such a law, if passed, would not prevent research from occurring in private institutions (such as universities) that have both private and federal funding. There are currently no federal laws in the United States which ban cloning completely, and any such laws would raise difficult constitutional questions similar to the issues raised by abortion.[citation needed] Fifteen American states (Arkansas, California, Connecticut, Iowa, Indiana, Massachusetts, Maryland, Michigan, North Dakota, New Jersey, Rhode Island, South Dakota, Florida, Georgia, and Virginia) ban reproductive cloning and three states (Arizona, Maryland, and Missouri) prohibit use of public funds for such activities.[citation needed]

Science fiction has used cloning, most commonly and specifically human cloning, due to the fact that it brings up controversial questions of identity.[64][65] Humorous fiction, such as Multiplicity (1996)[66] and the Maxwell Smart feature The Nude Bomb (1980), have featured human cloning.[67] A recurring sub-theme of cloning fiction is the use of clones as a supply of organs for transplantation. Robin Cook's 1997 novel Chromosome 6 and Michael Bay's The Island are examples of this; Chromosome 6 also features genetic manipulation and xenotransplantation.[68]

Read this article:
Human cloning - Wikipedia

Posted in Arkansas Stem Cells | Comments Off on Human cloning – Wikipedia

Puma Biotechnology (PBYI) Q4 Earnings: What’s in the Cards? – Zacks.com

Posted: March 4, 2017 at 10:43 am

Puma Biotechnology, Inc. (PBYI - Free Report) is expected to report fourth-quarter 2016 results next month. The company has a mixed earnings history. It missed estimates in two of the trailing four quarters, met expectations in one and surpassed the same in the other. The company had an average negative surprise of 2.98% in the last four quarters.

Pumas shares have outperformed the Zacks classified Medical-Biomedical and Genetics industry, year to date. Shares of the company gained 17.9% so far this year, while the industry recorded an increase of 6%.

Lets see how things are shaping up for this announcement.

Factors at Play

Being a development-stage company, Puma Biotech does not have any approved product in its portfolio. Thus, investor focus should remain on updates pertaining to the development of neratinib.

Puma Biotech has made significant progress with its lead candidate, neratinib. The candidate is currently under review in both the U.S. and the EU for the extended adjuvant treatment of HER2-positive early-stage breast cancer that has previously been treated with Herceptin-based adjuvant therapy.

We note that several phase II combination studies on neratinib for the treatment of breast cancer are currently underway.

In Dec 2016, Puma presented encouraging additional data from breast cancer studies at the San Antonio Breast Cancer Symposium (SABCS). These include data from HER2-positive early-stage breast cancer using loperamide and budesonide prophylaxis study; the FB-7 neoadjuvant HER2-positive breast cancer study in the subgroup of patients who are MammaPrint High; and data from neratinib plus AstraZenecas (AZN - Free Report) Faslodex in patients with HER2 non-amplified breast cancer with a HER2 mutation.

Earnings Whispers

Our proven model does not conclusively show that Puma Biotech is likely to beat estimates this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.

Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is pegged at 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of $2.02. You can uncover the best stocks to buy or sell before theyre reported with our Earnings ESP Filter.

Zacks Rank: Puma Biotechs carries a Zacks Rank #3. Though a favorable Zacks Rank increases the predictive power of ESP, the companys 0.00% Earnings ESP makes surprise prediction difficult.

Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.

Stocks That Warrant a Look

Here are a couple of health care stocks that you may want to consider, as our model shows that this have the right combination of elements to post an earnings beat this quarter.

Pacira Pharmaceuticals, Inc. (PCRX - Free Report) is scheduled to release fourth-quarter results on Mar 1. The company has an Earnings ESP of +20% and a Zacks Rank #2. You can seethe complete list of todays Zacks #1 Rank stocks here.

Syndax Pharmaceuticals, Inc. (SNDX - Free Report) has an Earnings ESP of +18.18% and a Zacks Rank #3. The company is scheduled to release fourth-quarter results on Mar 2.

A Full-Blown Technological Breakthrough in the Making

Zacks Aggressive Growth Strategist Brian Bolan explores autonomous cars in our latest Special Report, Driverless Cars: Your Roadmap to Mega-Profits Today. In addition to who will be selling them and how the auto industry will be impacted, Brian reveals 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>

See the article here:
Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards? - Zacks.com

Posted in Biotechnology | Comments Off on Puma Biotechnology (PBYI) Q4 Earnings: What’s in the Cards? – Zacks.com

iShares NASDAQ Biotechnology Index (ETF)(NASDAQ:IBB … – ETF Daily News (blog)

Posted: March 4, 2017 at 10:43 am

March 3, 2017 6:13am NASDAQ:IBB

From Taki Tsaklanos: Biotechnology stocks are breaking out. They have been consolidating for nearly 20 months. Investors lost interestand that is exactly what smart investors, in general, want to see in order to buy a market.

That is also how bull markets start: when nobody talks about it and only a minority of investors is buying it.

Now here it becomes interesting. InvestingHavens research team has closely followed biotechnology, and has written extensively about it last year. The red line throughout all articles was that smart investors are not in a hurry to buy biotech, but prefer to see which direction biotech would go. This is what was published on InvestingHaven until fall of last year:

Biotechnology Close To A Major Breakdown Level

Health Sector Testing All-Time Highs In 2016, Biotech A Buy After Breaking Out

Alert: Biotechnology and Health Sector Testing Long Time Support

Biotechnology Stocks Have News For Investors: It is Now or Never

In other words, on several occasions last year biotechnology stocks were ready to break down, but eventually they did not. The market refused to go lower, and that was a very important observation, which was shared with our readers: Biotechnology Stocks Refusing To Break Down

Then, something very interesting happened in January: Biotech And Health Care Stock Market Sector Showing Signs Of Life. That was the first sign that biotechnology stocks could go higher.

Today, they are attempting to break out.

The most interesting part was what InvestingHavens team wrote last year in April: Biotechnology Sentiment At Multi-Year Extremes. What Should Investors Do? Right at a time when a major breakout attempt in biotechnology stocks was at play, at a time when sentiment was extremely bullish, we wrote this:

What does all this mean to investors? Combining chart patterns with sentiment data is very useful for investors. We believe that a short term top has developed. Biotechnology needs to cool off a bit, which means a retracement is the most likely outcome for the coming weeks. The key is to watch how far the retracement will go: if prices remain within the existing pattern, above support, there is an opportunity for investors to buy the dips. As long as prices remain within the current chart pattern, it is not a good idea to short this market, unless you are a very short term oriented trader.

As a reminder, it was when IBB was trading at 280 points, in April last year, right before it fell 15 percent. Astute readers were very happy, and they keep on thanking us for our wise words.

Right now, biotechnology stocks are going through a serious attempt to break out from their 20-month consolidation period. If the 300 level in IBB holds for at least 5 consecutive days, biotech will go higher in the coming weeks and months.

The iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) was unchanged in premarket trading Friday. Year-to-date, IBB has gained 12.97%, versus a 6.59% rise in the benchmark S&P 500 index during the same period.

IBB currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #2 of 36 ETFs in the Health & Biotech ETFs category.

This article is brought to you courtesy of Investing Haven.

Tags: biotech Health Care NASDAQ:IBB Taki Tsaklanos

Categories: NASDAQ:IBB

Excerpt from:
iShares NASDAQ Biotechnology Index (ETF)(NASDAQ:IBB ... - ETF Daily News (blog)

Posted in Biotechnology | Comments Off on iShares NASDAQ Biotechnology Index (ETF)(NASDAQ:IBB … – ETF Daily News (blog)

Vet: stem cell technique could revolutionise equine medicine – vet times

Posted: March 4, 2017 at 10:43 am

A fast and cost-efficient technique for harvesting stem cells may have the potential to revolutionise the way vets treat orthopaedic conditions in horses.

The regenerative therapy, called Lipogems, uses fat tissue-derived mesenchymal stem cells from the tail head of the patient, which is prepared using a stable-side kit, meaning the procedure can be carried out immediately.

Historically, vets wanting to obtain stem cells would have to harvest fat tissue or bone marrow from the patient and send it to a laboratory for the cells to be cultivated and prepared for injection at another consultation a process that could take weeks and delay treatment.

In comparison, Lipogems allows the transplanting of lipoaspirate from fat tissue within 20 to 30 minutes of harvesting, said Lipocast Biotech UK, the company responsible for introducing the technique to the veterinary market for the first time.

Conditions treated to date include lesions of the superficial and deep flexor tendons, suspensory ligament desmitis (proximal, body and branch lesions), check ligament injuries and osteoarthritis affecting distal interphalangeal, fetlock and stifle joints.

Vet Tim Watson, of Waterlane Equine Vets in Gloucestershire, led initial work on the project.

In the past, people have cultured stem cells from fat tissues, but what this technique offers for the first time is the ability to extract stem cells in a quick, easy and relatively cost-effective way, so you can treat the horse immediately, Dr Watson said.

The technique means stem cell cultivation techniques are no longer the preserve of hospitals and laboratories.

Dr Watson said: Vets out on the road can do it. Potentially, it could revolutionise the way we treat orthopaedic conditions in horses.

There is nothing comparable with this technique in the industry.

Original post:
Vet: stem cell technique could revolutionise equine medicine - vet times

Posted in Cell Medicine | Comments Off on Vet: stem cell technique could revolutionise equine medicine – vet times

Page 1,633«..1020..1,6321,6331,6341,635..1,6401,650..»